← Metformin × all-cause mortality

Observational studyAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2025

Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study.

Emilie J Lambourg et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2025

Not counted

Probably increased deaths

+26%+10% to +44%

Bigger than 6 in 10 for all-cause mortality

As reported

HR 1.26, 95% CI 1.10–1.44 · the paper's word: All-cause mortality

Range includes no effect

No clear effect on deaths

+5%−12% to +26%

Bigger than 2 in 10 for all-cause mortality

As reported

HR 1.05, 95% CI 0.88–1.26 · the paper's word: All-cause mortality

Not counted

Probably increased deaths

+34%+8% to +67%

Bigger than 7 in 10 for all-cause mortality

As reported

HR 1.34, 95% CI 1.08–1.67 · the paper's word: All-cause mortality

Range includes no effect

No clear effect on deaths

+4%−19% to +33%

Bigger than 1 in 10 for all-cause mortality

As reported

HR 1.04, 95% CI 0.81–1.33 · the paper's word: All-cause mortality

Four numbers in the abstract

the abstract, start to end

… vs 70.5% [95% CI, 68.0-73.0]; HR, 1.26 [95% CI, 1.10-1.44]), and the incidence of MACE was similar between both strategies (HR, 1.05 [95% CI, 0.88-1.26]).

… metformin (all-cause mortality: HR, 1.34 [95% CI, 1.08-1.67]; MACE: HR, 1.04 [95% CI, 0.81-1.33]).

← favours treatmentfavours comparator →
could be chance
All-cause mortality
HR 1.261.10–1.44
All-cause mortality
HR 1.050.88–1.26
All-cause mortality
HR 1.341.08–1.67
All-cause mortality
HR 1.040.81–1.33
MetforminAll-cause mortality
1 / 3

3 papers cite it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 39521399